Prof. Xinrong Yang 杨欣荣
Chief Physician, Professor
Department of Hepatobiliary Oncology and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of liver tumors, including minimally invasive surgery; liver transplantation and post-operative management; comprehensive treatment of primary and secondary liver cancer; diagnosis and treatment of gallbladder cancer and hilar cholangiocarcinoma.
Dr. Yang is a Chief Physician and Professor at Zhongshan Hospital, Fudan University. Holding an MD and PhD, Dr. Yang trained under Academician Fan Jia. Career milestones include short-term study at Memorial Sloan Kettering Cancer Center (2010) and a senior visiting scholar role at Queen Mary Hospital, University of Hong Kong (2019). Dr. Yang performs approximately 200 liver surgeries and 50 liver transplants annually. Research focuses on liver cancer metastasis, recurrence, circulating tumor cells, ctDNA, and animal models.
Professional roles
- Youth Committee Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Youth Committee Member, Colorectal Cancer Liver Metastasis Branch, China International Exchange and Promotion Association for Medical and Healthcare
Name order: in Chinese the family name comes first (Yang Xinrong). Papers usually list the name as Xinrong Yang or Yang X.
Selected publications
154 papers on PubMed matched by name and affiliation; 42 as first or senior author since 2016. Most recent first- or senior-author papers:
- iScience, 2026 (senior author): Decomposition-driven biomarker identification enhances non-invasive early cancer detection. PubMed 42835240
- Cancer Lett, 2026 (senior author): Multi-omic profiling identifies TREM2(+) lipid-laden macrophages as inflammatory drivers and therapeutic targets of colorectal cancer liver metastasis. PubMed 42250756
- J Immunother Cancer, 2026 (senior author): Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma. PubMed 42082269
- Clin Transl Med, 2026 (senior author): Glucose metabolic reprogramming as a driver of immunosuppression in the tumour microenvironment. PubMed 42163583
- Nat Commun, 2025 (senior author): Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation. PubMed 41249197
- Liver Cancer, 2025 (senior author): (18)F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. PubMed 40242795
- Hepatology, 2025 (senior author): Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution. PubMed 40833994
- Sci Bull (Beijing), 2025 (senior author): Exploring morphological heterogeneity of circulating tumor cells: machine learning-based approach for cell identification and prognostic implications. PubMed 40348669
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion